Join our daily newsletter At The Bell to receive exclusive market insights
- Clinical stage immuno-oncology company Imugene (IMU) granted a European patent for its HER-Vaxx immunotherapy technology which is designed to treat cancer
- The patent entitled “A Vaccine Composition and Uses Thereof” protects the method of composition and use of HER-Vaxx in Europe until 2036
- HER-Vaxx is designed to treat tumours that over express the HER-2 receptor, a cause of gastric, breast, ovarian, lung and pancreatic cancers
- The company says pre-clinical trials show HER-Vaxx stimulates a potent antibody response to the HER-2 receptor
- Shares were trading at 28 cents at close of market January 27
Clinical stage immuno-oncology company Imugene (IMU) has been granted a European patent for its HER-Vaxx immunotherapy technology which is designed to treat cancer.
The patent entitled “A Vaccine Composition and Uses Thereof” protects the method of composition and use of HER-Vaxx in Europe until 2036.
HER-Vaxx is designed to treat tumours that over express the HER-2 receptor, a cause of gastric, breast, ovarian, lung and pancreatic cancers.
The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2.
The company said pre-clinical trials show HER-Vaxx stimulates a potent antibody response to the HER-2 receptor.
MD and CEO Leslie Chong said attaining the European patent is an important milestone.
“Attaining the key European patent is an important milestone and is another major pharmaceutical market to grant patent protection for HER-Vaxx until 2036,” she said.
The company said its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours.
Shares were trading at 28 cents at close of market January 27.
